Literature DB >> 6104083

Comparison of trimethoprim alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance.

R W Lacey, V L Lord, H K Gunasekera, P J Leiberman, D E Luxton.   

Abstract

279 patients were treated with 100 mg trimethoprim or 100 mg trimethoprim combined with 500 mg sulphamethoxazole (co-trimoxazole) twice daily for 5 days in a prospective randomised double-blind trial. In chest infections in patients in general practice and in an acute geriatric assessment unit, the efficacy of each regimen was similar, but there were more side-effects with co-trimoxazole than with trimethoprim alone. In urinary-tract infections the two regimens also produced similar cure rates. Treatment with trimethoprim rarely selected resistant pathogens in the sputum or resistant Enterobacteriacae in the intestine, although the incidence of resistant coagulase-negative staphylococci on the skin increased with both regimens. Most chest and urinary infections hitherto treated with co-trimoxazole should be treated with trimethoprim alone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104083     DOI: 10.1016/s0140-6736(80)91732-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Increase in bronchopulmonary infection due to branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; S Capewell; M J Croughan; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-26

Review 3.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

Authors:  Andrew M Wilson; Allan B Clark; Tony Cahn; Edwin R Chilvers; William Fraser; Matthew Hammond; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David R Thickett; Moira Whyte
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 5.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

Review 6.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

7.  Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12.

Authors:  S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Single dose trimethoprim for urinary tract infection.

Authors:  T Nolan; L Lubitz; F Oberklaid
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

9.  Trimethoprim and co-trimoxazole in the treatment of acute urinary tract infections: patient compliance and efficacy.

Authors:  D A Andrewes; P J Chuter; M J Dawson; B W Eden; R M Moore; D S Freestone; C A Morris
Journal:  J R Coll Gen Pract       Date:  1981-05

10.  Emergence of trimethoprim resistance in fecal flora.

Authors:  P Huovinen; T Mattila; O Kiminki; L Pulkkinen; S Huovinen; M Koskela; R Sunila; P Toivanen
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.